Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia

NCT02688764 is registered in ClinicalTrials.gov with Vifor Fresenius Medical Care Renal Pharma as lead sponsor.

NCT NCT02688764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02688764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia
Lead sponsor
Vifor Fresenius Medical Care Renal Pharma
Phase
Phase 3
Overall status
Terminated
Start date
May 26, 2016
Completion date
February 21, 2019
Enrollment
85 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

hyperphosphatemia